ESSA Pharma Inc. Share Price Toronto S.E.
Equities
EPI
CA29668H7085
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 38Cr 28Cr 2.3TCr |
---|---|---|---|---|---|
Net income 2024 * | -4.6Cr -3.38Cr -281.26Cr | Net income 2025 * | -7.2Cr -5.29Cr -440.23Cr | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-8.22
x | P/E ratio 2025 * |
-6.13
x | Employees | 50 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.45% |
Latest transcript on ESSA Pharma Inc.
Managers | Title | Age | Since |
---|---|---|---|
David Parkinson
CEO | Chief Executive Officer | 73 | 24/15/24 |
David Wood
DFI | Director of Finance/CFO | 66 | 01/13/01 |
Peter Virsik
COO | Chief Operating Officer | - | 01/16/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Franklin Berger
BRD | Director/Board Member | 74 | 05/15/05 |
Sanford Zweifach
BRD | Director/Board Member | 68 | 31/19/31 |
Richard Glickman
CHM | Chairman | 65 | 01/10/01 |
1st Jan change | Capi. | |
---|---|---|
+33.37% | 5.08TCr | |
+1.55% | 4.28TCr | |
+49.39% | 4.2TCr | |
-4.22% | 2.95TCr | |
+11.57% | 2.61TCr | |
-21.00% | 1.91TCr | |
+7.36% | 1.31TCr | |
+28.30% | 1.22TCr | |
+23.80% | 1.21TCr |